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Macrophage signal transduction by  
p110δ PI3K 
Klaartje Kok, Kaushal Parikh, Sander Diks, Jos Joore, Bart 




The delta isoform of the catalytic subunit of PI3 kinase (p110δ) is mainly expressed in 
cells of the immune system and contributes to cellular and humoral immunity. Defining 
the molecular effects of this isoform at cell physiological level has remained 
problematic, also with regard to its effects on lipopolysaccharide (LPS)-induced 
signalling. To study the effects of p110δ without a priori assumptions, we compared the 
capacity of macrophage lysates made of cells genetically deficient in p110δ enzymatic 
activity (p110δD910A/D910A) and control macrophages for in vitro phosphorylation of 
peptide arrays, containing 976 different kinase consensus substrates. The results provide 
a wealth of data on p110δ effects in macrophage physiology and reveal a modulatory 
role of this enzyme in LPS-dependent signalling. Genetic ablation leads to enhanced 
LPS signalling with respect to the Rac- and Rho- dependent pathways, p38 MAP kinase 
and JNK signalling, but also to diminished Syk, p42/p44 MAP kinase and protein 
kinase B-dependent pathways. Thus our results reveal a dichotomal role of p110δ in 




The 3-phosphoinositide lipids, generated by phosphoinositide 3-kinases (PI3Ks), are 
second messengers that regulate a broad variety of cellular responses such as growth, 
proliferation, survival, differentiation, intracellular traffic and cell migration [1]. Class 
IA PI3Ks generate 3-phosphoinositide lipids following receptor stimulation. They are 
heterodimers made up of a 110 kDa catalytic subunit (p110α, p110β and p110δ) and 
one of five regulatory subunits (collectively called “p85s”). Whereas p110α and p110β 
are universally expressed throughout mammalian tissues, the expression of p110δ is 
most prominent in leukocytes [2-5], suggesting that this isoform participates in 
leukocyte-specific signal transduction events. Indeed, it has become clear that p110δ 
PI3K plays important functions in macrophage chemotaxis [6], antigen receptor 
responses in T cells and B cells [7], and mast cell responses to allergic stimuli [8].  
Class IA PI3K  isoforms often exert distinct biological roles downstream of
specific receptors in various cell types. It is also clear that a given PI3K isoform can 
take up distinct roles in different cellular contexts [9], as is illustrated above by the 
different roles of p110δ in different cell types and downstream of different receptors. 
The pleiotropic nature of p110δ PI3K is further illustrated by studies showing that in 
macrophages, p110δ inactivation leads to reduced Rac and protein kinase B (PKB) 
activation, but increased RhoA and PTEN activation [10], while in natural killer cells, 
p110δ positively regulates p42/p44 MAP kinase activation, but negatively regulates p38 
MAP kinase [11].  
Mice lacking catalytic active p110δ PI3K, p110δD910A/D910A mice, develop 
inflammatory bowel disease (IBD) [7]. IBD arise as a result of abnormal innate 
immunity to enteric flora [12]. Various studies show an inhibitory role for PI3Ks in 
innate immune responses. p85α-/- mice develop increased immune responses upon 
Leishmania major infections [13] and pharmacological inhibition of PI3K activity 
exacerbates microbial sepsis  [14,15]. Furthermore, microbial agents that activate cells 
of the immune system to produce cytokines also activate class IA PI3Ks   [13,16-20] 
and PI3Ks suppress cytokine production triggered as was shown by an increase in 
cytokine production upon absence or inhibition of PI3K [13,19,21]. 
This raises the question whether p110δD910A/D910A mice develop IBD as a result 
of enhanced, harmful, innate immune signalling in the absence of active p110δ and 
prompted us to study the role of p110δ PI3K in innate immune signalling. Kinome 
profiles, cytokine production and protein phosphorylation were compared in 
macrophages from p110δD910A/D910A WT/WT mice (D910A) versus p110δ  (WT)  
macrophages in response to stimulation with the bacterial wall component 
lipopolysaccharide (LPS). The results show a dichotomal role of p110δ in these cells, 
acting as a negative regulator of the pro-inflammatory p38 MAP kinase and Jun-N-
terminal kinase pathways, but acting as a positive regulator for the PKB, Syk, and 
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p42/p44 MAP kinase signalling. These data provide insight into the actions of p110δ 





Phosphorylation of peptide arrays 
Establishing the molecular function of genes action is difficult if there is little 
information about the biochemical details of the biological effect observed. In the 
present study, we first set out to obtain kinome profiles, using a peptide array containing 
976 different kinase specific consensus sequences and 48 control sequences. The 
method as first described by Diks et al. [22], allows a comprehensive detection of the 
cellular metabolism in whole cell lysates and has been used as such in various 
experimental systems generating comprehensive insight into signal transduction under 
various conditions [23-26]. Here we employed this technique to characterise the role of 
p110δ  in murine bone marrow macrophages. 
Kinome profiles were generated by incubating the peptide arrays with 33P-γ-ATP 
and  cell lysates from bone marrow-derived macrophages from WT or D910A after 10 
minutes stimulation with 100 ng/ml LPS or vehicle controls. Arrays incorporated 
substantial amounts of radioactivity. Radioactivity incorporation involved the covalent 
transfer of the terminal phosphate group of the ATP to peptide substrates, as incubation 
of arrays with cell lysates and 33P-α-ATP did not produce meaningful incorporation of 
radioactivity into arrays. The technical quality of the profiles was good as the average 
Pearson product moment correlation coefficient was in excess of 0.85 between the 
technical replicas in all experimental groups (Figure 1).  
We then determined the number of significantly phosphorylated substrates by 
calculating for each peptide the average and standard deviation of the substrate 
phosphorylation  (a full list of significantly phosphorylated peptides can be found in 
Table 1, other peptides not shown) and plotting the values obtained in an amplitude-
based hierarchical fashion (Figure 1, panels iv). If only background phosphorylation 
was present, this amplitude-based distribution can be described by a single exponent 
(red lines in Figure 1, panels iv) and peptides of which the average phosphorylation 
minus 1.96 times the standard deviation was in excess of the value expected from the 
function describing the background distribution were considered to represent true 
phosphorylation events. This yielded approximately 100 significantly phosphorylated 










































peptide arrays exhibiting 976 different kinase substrates with  33P‐γ‐ATP and cell  lysates  from 













Global comparison of kinome profiles suggests a role for p110δ  in the negative 
control of macrophage LPS responses 
To investigate the relationship between the different experimental conditions, Venn 
diagrams depicting the similarity between the four sets of significantly phosphorylated 
peptides were constructed (Figure 2). Strikingly, kinome profiles obtained from 
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unstimulated bone marrow-derived macrophages obtained from animals genetically 
deficient for p110δ  most closely resembled the profiles of LPS-stimulated bone 
marrow-derived macrophages obtained from wt animals. Also when the amplitude 
information of the entire datasets were employed and subjected to clustering according 
to Johnson [27], profiles of unstimulated  macrophages obtained from p110δ -deficient 
animals clustered with profiles of LPS-stimulated macrophages obtained from wt 
animals (Figure 3). The most straightforward explanation of these results is that p110δ  







































A dichotomal role for p110δ  in LPS signal transduction 
To obtain further insight into the effects of p110δ on LPS signal transduction in 
macrophages, kinome profiles following LPS stimulation were investigated for 
substrates that show statistically significant differences in phosphorylation between WT 
and D910A macrophages. A description of these results is given in Table 1  and would 
seem to support the conclusion that genetic deficiency for p110δ leads to LPS-
stimulated-like phenotype. When the results were employed to construct provisional 
signal transduction schemes a more subtle picture emerged, however (Figure 4). Lack of 
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catalytic active p110δ PI3K clearly resulted in upregulation of the important pro-
inflammatory stress-activated MAP kinase pathways upstream of p38 MAP kinase and 
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Figure  3:  Clustering  of  kinome  profiles.  A  global  comparison  of  all  amplitude  information 
obtained  in  the peptide  array  experiments  and  subsequent  clustering  according  to  Johnson 




Also Rho- and Src-dependent signals were upregulated in macrophages derived from 
p110δD910A/D910A mice. Signalling though the PKB signalling pathway was down 
regulated, not surprising in view of lack of activity of p110δ PI3K and confirming 
validity of the peptide array. Interestingly, also down regulated in cells not displaying 
p110δ activity are Syk and the p42/p44 MAP kinase cascade, indicating a role of this 
subunit in their activation following LPS stimulation. Western blot analysis confirmed 
these effects, clearly showing diminished LPS-dependent p42/p44 MAP kinase 
phosphorylation and PKB phosphorylation in p110δ-deficient macrophages (Figure 5A 
and 5B). Furthermore, pharmacological inhibition of p110δ, using the p110δ specific 
inhibitor IC87114 [28] recapitulated the effect of genetic ablation of p110δ activity on 
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LPS-induced kinase activation (Figure 5), showing that the effects observed in the 
macrophages derived from genetically-modified animals reflect direct defects of p110δ 
in the macrophage signal transduction machinery and are not the result of the chronic 
absence of this kinase during macrophage development. Hence, the role of p110δ in 



























































Innate immunity is essential for the body to avoid succumbing to opportunistic 
microbiological infection, but must be strictly controlled to avoid unnecessary collateral 
damage to the tissues. The levels at which this control is exercised are still only partly 
understood. In the present study we have characterised the role of p110δ in this 
response employing an unbiased kinome profiling approach. It appears that p110δ 
interacts with this signalling in multiple ways, acting as negative regulator of pathways 
that provoke transcription of pro-inflammatory mediators, especially the Jun-N-terminal 
kinase and p38 MAP kinase pathways. At the same time, however, p110δ-deficient 
macrophages show diminished activation of PKB/p70 S6 kinase, Syk, and p42/p44 
MAP kinase pathways, which have instrumental functions in LPS signalling as well. 
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Hence, this study highlights a delicate role of p110δ in macrophage pro-inflammatory 
signal transduction. 
 

















Figure 5:  LPS activates Akt  signalling  in wildtype bone marrow‐derived macrophages. This 
effect  is p110δ PI3K dependent as  is shown by reduction of phosphorylation after treatment 
with  the p110δ‐specific  inhibitor  IC87114  (A).  (B) phosphorylation of p42/44  in macrophages 
upon LPS  stimulation  is p110δ PI3K dependent as  is  shown by  reduction of phosphorylation 




The observed down regulation of PKB activity and consequent upregulation of 
GSK3-ß highlights the importance of the p110δ isoform for total PI3K activity for 
leukocyte biology. The prominence of this effect may be partly indirect, recently it was 
shown that p110δ negatively influences the phosphoinositide phosphatase PTEN and 
that the catalytic inactivity of specifically p110δ leads to enhanced activity of this 
phosphatase [10]. As this phosphatase counteracts PI3K signalling in general (so also 
that of p110α- and p110β-derived phosphoinositides [29]), this effect may amplify the 
effects of genetic ablation of p110δ on the entire complement of leukocyte 
phosphoinositide signalling. Interestingly, pharmacological inhibition of the Rho 
effector kinase Rock counteracts the effects of lack of active p110δ on PTEN [10], 
suggesting that negative regulation of the Rho/ROCK pathway mediates p110δ effects 
on PTEN activity and in consistency with these data we observe diminished ROCK 
activation in kinome profiles from cells lacking p110δ enzymatic activity. This supports 






Interestingly, many of the features observed following genetic ablation of p110δ 
catalytic activity on macrophage signal transduction seem reminiscent to effects 
reported in the natural killer cell compartment of the innate immune system [11]. In this 
system, loss of p110δ activity is associated with enhanced p38 MAP kinase activity and 
reduced p42/p44 MAP kinase activation, effects also seen in the kinome profiles 
obtained in the current study. Thus, p110δ as a negative regulator of important aspects 
of cellular activation seems to emerge as a general theme in the leukocyte compartment.  
Also interesting are the effects of p110δ inactivity on Syk. Activity of this kinase 
is reduced in the absence of active p110δ. Recently it was established that Syk-mediated 
translocation of p110δ to the leading edge controls lamellipodium formation and 
migration of leukocytes [30]. The results obtained in the present study suggests that this 
relationship is reciprocal, p110δ being important for the activation of Syk, in turn Syk 
may subsequently mediate appropriate subcellular localisation of p110δ. Further 
experimentation is obviously necessary to substantiate this notion. 
In conclusion, the kinome profile data generated in the present study shed 
important light on the multiple intersecting pathways through which p110δ controls 
innate responses in macrophages. The results reveal a dichotomal role of the protein, 
although its action seems mainly inhibitory on signalling, which seems consistent with 
results reported in the natural killer cell compartment.  Thus it should prove interesting 
to investigate other cell types with high levels of p110δ expression as well with kinome 




      Significantly phosphorylated peptide substrates in 
     WT WT D910A D910A 
Sequence Source protein for peptide Putative upstream kinase  +LPS  +LPS 
       
KRQYGTISHGI Amyloid precursor like protein 2 PKC yes yes yes yes 
VLAQPSTSRKR CHK2 ATM / PKA;PKG yes yes yes yes 
MRKKISNAQLQ Cullin 5 PKA yes yes yes yes 
LRRRLSDSNFM Synapsin I CaMKI;PKA yes yes yes yes 
RKKKVSSTKRH Cytohesin-1 PKCdelta yes yes yes yes 
VPKRKSLVGTP p21 activated protein kinase 6 nd yes yes yes yes 
LARRPSYRKIL Activating transcription factor 1 CaMKII  / CaMKI;PKA;S6K yes yes yes yes 
TRVPPSRRGPD Alpha 2A adrenergic receptor PKC yes yes yes yes 
GFSRKSHTFLP CNPase PKC yes yes yes yes 
ASRPSSSRSYV Vimentin PAK yes yes yes yes 
KKKIATRKPRF Metabotropic glutamate receptor 1 PKC yes yes yes yes 
WRRKSSDRKGG HLA-A Protein_kinase,_cAMP_dependent,_regulatory,_type_I,_alpha yes yes yes yes 
RLRPLSYPQTV Ras related C3 botulinum toxin substrate 1 AKT1 yes yes yes yes 
RKRKNSRVTFS NIPP1 PKA yes yes yes yes 
IKRQLSMTLRG PCTAIRE protein kinase 1 PKA yes yes yes yes 
RARSTSLNERP Tuberin AKT1 yes yes yes yes 
NSRRPSRAMWL Vitronectin PKA yes yes yes yes 
LRRRLSDSSFI Synapsin II PKA yes yes yes yes 
RTRRISQTSQV Ryanodine receptor 2 PKA yes yes yes yes 
GKNRPSSGSLI Quinoid dihydropteridine reductase CAMKII yes yes yes yes 
TKALQSPKRPR TFII-I EphB2 yes yes yes yes 
KIRRLSAAKQQ LKB1 PKA/ p90RSK;MSK1;S6K1;PKA;LKB1 yes yes yes yes 
IAVRKSRDKAK CCAAT/Enhancer binding protein, beta ERK2 yes yes yes yes 
RLRPRTRKVKS Neutrophil cytosolic factor 4 40kDa PKC yes yes yes yes 
RGKKKSGALVL RhoA PKA yes yes yes yes 
KIGEGTYGVVY CDC2 Tita: WEE/MYT PK161 yes yes yes yes 
RSNPPSRKGSG Connexin 32 PKC;PKA yes yes yes yes 
EPQRRSARLSA HMG17 Ribosomal_protein_S6_kinase_alpha_3;PKA;PKC yes   yes yes 
SRKGYSRKGFD Peptidylglycine alpha amidating monooxygenase PKC yes   yes yes 
GFTRKSVRKAQ Protein phosphatase 2, rs B56, alpha PKR yes   yes yes 
RRRAASMDSSS AFX 1 AKT1 yes   yes yes 
LNRIQTQIRVV ATP2B1 PKC yes   yes yes 




EAKRKSPKKKE Coilin CDK2-cyclin_E yes   yes yes 
SVRMLSGSKEK Opioid receptor mu 1 CAMKII yes   yes yes 
EKARLSYSDKN Protein kinase C delta PKCdelta yes   yes yes 
LTRIPSAKKYK PEA15 PKC yes   yes yes 
TKWYRSPRLLL MAPK4 MAPK4 yes   yes yes 
GPRLVSNHSLH Filamin A CAMKII yes   yes yes 
QKIHISKKWGF Ribosomal protein L10 RPL10 yes   yes yes 
GLRRSSKFALK Beta-2-adrenergic receptor PKC yes   yes yes 
VMVTASHNPEE Phosphoglucomutase 3 PAK1 / nd yes       
KPKDASQRRRS c-Src PKC yes     yes 
KALPLSPRKRL CDC6 CDK2 yes yes yes   
PSRKGSGFGHR Connexin 32 PKC yes yes   yes 
SILPFTPPVVK SMAD2 ERK yes       
VGKIFSNVRIN Caveolin 1 CK2 yes     yes 
KFSKFSLYKQL PLD1 PKCalpha yes       
AVRLRSSVPGV Vimentin Rho_kinase yes yes     
GMDYRSAILRP Thimet oligopeptidase 1 PKA yes yes yes   
RPRSATWPLQR Forkhead box protein O3A Serum/glucocorticoid_regulated_kinase;AKT1 yes     yes 
GSRRSSAIGIE RAP1 GTPase activating protein 1 PKA (neg. to Ras) yes       
LSRMGSLRAPV E2F transcription factor 1 CHK2 yes yes   yes 
GRLRKSLPSLL Complement component 5 receptor 1 nd yes       
FWSTLSPIAPR ELK 1 p38MAPK / MAPK14;p46SAPK;p54SAPK yes yes     
RLKSISERLSV Aquaporin 0 PKA yes     yes 
SSRRQSVLVKS Glutamate receptor, ionotropic kainate 2 PKA yes     yes 
KVRFNSVSSYS Nitric oxide synthase 1 PKG / CAMKIIalpha;CAMKIalpha;CAMKIV;PKA;PKC yes       
RRGDSYDLKDF VAV1 ZAP70 / PKA yes   yes   
FPAPQTPGRLQ ADAM 17 EphB2 yes yes yes   
RKRRWSAPESR Ataxin 1 Akt / ATK1 yes yes yes   
KKRKRSRWNQD Splicing factor 1 PKG-1 yes yes     
RGRGSSVGGGS ASK1 AKT1 yes       
GQLRGSATRAL Casein kinase 1, epsilon CK1epsilon yes yes     
LMKSDSYPRFI Regulator of G protein signaling 7 PKCalpha yes       
DAPPLSPFPHI Retinoblastoma like 1 CDK4 yes       
QERRGSNVALM Protein tyrosine phosphatase nonreceptor 7 PKA yes   yes   
VHRDLSRDRPL Kell blood group protein PKC yes yes yes   
APKAPSKKEKK DAB2 PKC yes     yes 
SDSRKSMRQST TCFL1 PKC yes yes   yes 
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PSAYGSVKAYT Annexin II PKC yes       
NRSFLSLKHTP Notch2 GSK3beta / nd yes yes   yes 
RRAKHYVELLV Vanilloid receptor like channel 2 Lyn yes   yes   
LSNPAYRLLLA Discoidin domain receptor Discoidin_domain_receptor yes       
RGQEVYVKKTM TEK receptor tyrosine kinase autophosphorylation / nd yes yes   yes 
PSGLWSPAYAS NUP210 CyclinB;p34cdc2 yes       
GARRSSWRVIS 14-3-3-Eta SDK1 is proteolytic fragment of PKC delta yes yes yes   
KTKFASDDEHD Autoantigen La nd yes       
GTLRTSISVER Bradykinin receptor 2 PKC yes     yes 
EVERTYLKTKS Glutamate receptor ionotropic, NMDA2A Src yes   yes   
QEQESSGEEDS Protein phosphatase inhibitor 2 CK2 yes       
RRRFSSLHFMV Caspase 9 ERK1;ERK2;MEK1;MAP2K2 yes       
RKKRISVKKKQ Cytohesin 2 PKC yes yes     
LKPGSSHRKTK Bruton's tyrosine kinase PKCbeta yes yes     
SQRRESFLYRS cAMP-specific 3',5'-cyclic phosphodiesterase 4B PKA yes yes yes   
KARKKSSAQLL Ras related protein Rap 1B PKA yes yes yes   
EKKAYSFAGTV Ribosomal S6 kinase 1 Pyruvate_dehydrogenase_kinase,_isoenzyme_1 yes     yes 
RKRKPSTSDDS DNA topoisomerase II alpha CK2 yes yes     
AAKRASRIYNT Regulator of G protein signaling 10 PKA yes yes yes   
PSSRASSRASS Connexin 43 nd yes   yes   
RPRNYSVGSRP 6-phosphofructo-2-kinase AKT yes yes     
PAARASKKILL Beta-adrenergic receptor kinase1 PKC yes yes     
LERNLSFEIKK Protein tyrosine phosphatase, nonreceptor-type, 12 PKA;PKC yes yes     
LLSELSRRRIR eIF2 alpha PKR;GCN2;Eukaryotic_translation_initiation_factor_2a K3 yes yes     
KKGARSRRLFS 
Guanine nucleotide binding protein, alpha 15 
subunit PKCalpha yes   yes   
RSKKNSLALSL Estrogen receptor, alpha PAK1 yes     yes 
KDFSSSKRMNT Syntaxin binding protein 1 PKC yes yes yes   
IKRLRSQVQVS Hepatocyte nuclear factor 4-alpha AMPK yes       
AMRNFSRSDHL Early growth response  protein 1 CK2 yes   yes   
RKGHEYTNIKY SHP2 PDGFRbeta yes yes     
RQRSTSTPNVH RAF1 PKA;AKT1 yes yes     
RSRSRSPRPRG ErbB3 Phospholipid_kinase_Phosphoinositide_kinase   yes     
RTAKDSDDDDD Syntaxin 1A CK2   yes     
GFTEESGDDEY TCFL1 CK2   yes yes   
VLDDEYVSSFG Protein tyrosine kinase TXK Lyn, Fyn   yes     
FLSSPTYRALL Regulator of G protein signaling 19 PKC   yes     




FMRRTSLGTEQ EP4 receptor PKA   yes     
AIRRASTIEMP Phospholamban PKA   yes     
ELRRMSDEFVD BCL2 antagonist of cell death PKA;AKT1   yes     
IRYIESLQELL Myogenic factor 5 CK2   yes     
PELARYLNRNY Hrs tyrosine kinases / EGFR   yes     
GGDDIYEDIIK VAV2 lck / nd   yes     
GDAAETPPRPR MEK1 CDK5   yes     
TGLYKSQRPAV BTEB2 PKC   yes   yes 
PPVPATPYEAF SPIB transcription factor ERK1   yes   yes 
YRERMSSNRPN Meprin,beta subunit PKC   yes     
KQQPGSPRRIS Retinoblastoma like 1 nd   yes yes yes 
LRRQHSYDTFV NR2B CaMKII;PKC   yes yes yes 
DEELHYASLNF CD33 Src_kinase   yes yes   
EDTTSTFAGTP Serum/glucocorticoid regulated kinase 2 3-Phosphoinositide_dependent_protein_kinase_1   yes     
GSRRGSFDATG Desmoplakin PKA   yes     
KVGVSSRINEW CALDESMON 1 CDC2_Kinase   yes yes yes 
LPVPEYINQSV EGF receptor EGFR   yes     
RKAKRSLAPRF PKR PKR   yes     
PLVQRGSANGL Beta-adrenergic receptor kinase1 PKA   yes yes   
RPRVTSGGVSE Cell cycle checkpoint kinase I ATR   yes     
RRRRPTPAMLF Protein phosphatase 1, regulatory subunit  1B PKA   yes yes   
FESIESYDSAD C ets 1 protein CaMK2   yes     
IHMVYSKRSGK Small nuclear ribonucleoprotein 70 kD CLK (regulates splicing) / nd   yes yes   
KAARKSAPSTG H3 histone, family 3A MSK1/2 / nd   yes     
RDKYKTLRQIR Moesin Rho-Kinase   yes yes   
ASGYISSLEYP Complement component 1, subcomponent r CK2   yes     
DFEGFSYVNPQ Protein kinase C alpha PKCalpha   yes     
RRRMASMQRTG E1A binding protein p300 AKT;p70S6_kinase;pp90Rsk   yes     
SRKRLSQDAYR p47-phox PKCalpha;PKCbetaII;PKCdelta   yes     
PTPPLSPSRRS c-Myc CK2;GSK   yes     
QLRRPSDRELS NFKB3 PKA   yes     
AERRFSRSDQL WT1 PKA   yes yes   
ASKRSYQFWDT N-Myristoyl transferase 1 Lyn   yes yes   
TGSVDYLALDF GAB2 RTK, activation of SHP / ZAP70   yes     
YKVILYELENF Crystallin beta B3 nd   yes yes   
TTSQLYDAVPI 3-Phosphoinositide dependent protein kinase 1 c-Src   yes yes   
QSKRSTMVGTP PAK3 Pyruvate_dehydrogenase_kinase,_isoenzyme_1   yes yes   
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QERRKYLKHRL STAT2 JAK1   yes     
GLMQQQKSFR SHP2 PKCalpha;PKCbeta1;PKCbeta2;PKCeta   yes yes   
ALRRESQGSLN Regulator of G protein signaling 14 PKA   yes     
RRGSDSSEDIY Protein phosphatase 1, regulatory subunit 3A Ribosomal_S6_kinase_1   yes yes   
LSRRPSYRKIL cAMP response element-binding protein 1 PKA;MAPK;CaMK;RSK2   yes     
KKKKPSRLKGD APC PKA   yes     
FEEDDYESPND SLP 76 ZAP70_Protein_tyrosine_kinase_TXK   yes yes   
VSFNPYEPELA SYK SYK   yes     
PGLDEYNPFSD SCAMP1 EGFR   yes yes   
APEDLYKDFLT VEGF receptor 2 VEGF_receptor_2   yes     
RNEGVYTAIAV PSTPIP1 ABL   yes     
APLLSTPKRER Kinesin like 4 Cyclin_B2   yes     
ADDSYYTARSA ZAP70 Lck   yes     
QQQEVYGMMPR Spectrin Csk   yes   yes 
PPTGATANRLR Casein kinase 1, epsilon CK1epsilon   yes     
FFVIEYVNGGD Protein kinase C, iota type c-Src   yes     
LLEDDSDEEED Vesicle associated membrane protein 4 CK2alpha_1   yes yes   
MRRSVSEAALA Lipase hormone sensitive nd   yes     
KSKIGSTDNIK Microtubule associated protein 2 MARK   yes     
PSMRSSGTDRK HOX B7 CK2alpha1   yes     
GSKNKSPSKAA High mobility group AT-hook 2 Cdc2_kinase   yes     
GSHSNSFRLSN Protein tyrosine phosphatase, receptor type, alpha PKCdelta   yes     
PGLRRSPIKKV B-Myb CDK2   yes yes yes 
QHRSSSSAPHH Calcium channel  voltage dependent  beta 2 subunit DNA-dependent_protein_kinase_catalytic_subunit   yes     
QVKALYDFLPR Protein tyrosine kinase TXK Protein_tyrosine_kinase_TXK   yes     
SSTHYYLLPER ACK nd   yes     
GQVIMSIRTKL Ribosomal protein L10 Ribosomal_protein_L10   yes     
ALVHSYMTGRR SH2D3A nd     yes   
SRRPKSSLPPV Myosin light chain kinase PAK2     yes yes 
GLYSRSGSLSG PKN PKN     yes   
QARANSFVGTA 3-Phosphoinositide dependent protein kinase 1 PDK1     yes   
TIPPKYRELLA Calpastatin c-Src     yes   
SDEVQSPVRVR PCTAIRE protein kinase 1 CDK_5     yes   
RRRAVSMDNSN Forkhead box protein O3A AKT1     yes   
SDSLSSPTLLA c-Fos EphB2;ERK2     yes   
DGKEIYNTIRR RasGAP EGFR;Lck nota bene negatively regulates GAP     yes yes 




PEFPLSPPKKK Stathmin 1 p34cdc2     yes   
IKEDVYLSHDH Protein tyrosine kinase 6 Lck/Protein_tyrosine_kinase_6     yes   
GSPSVRASSMS SMAD2 Activin_receptor_like_kinase_4_TGF_beta_receptor,_type_I     yes   
IPRRTTQRIVA Collapsin response mediator protein 2 Rho-kinase     yes yes 
IPTGTTPQRKS Kinesin like protein 1 p34cdc2;cyclin_B     yes   
MSSPPPARSG MAPK12 p38MAPKgamma / MAPK12     yes   
DTLSDSDDEDD N-myc CK2     yes   
RSGLASPSYVA c-Myc JNK1     yes   
GTGDTSSEEDE Transcription factor IIA, 1 CKI / CK II / TFIID;CK2     yes   
RTRTDSYSAGQ mTOR PI3K pathway (autophos?) /AKT     yes   
SDTTTTFAGTP Serum/glucocorticoid regulated kinase 3 3-Phosphoinositide_dependent_protein_kinase_1     yes   
LEVSDSESDEA SPIB transcription factor CK2     yes   
ALDFRTPRNAK Opioid receptor mu 1 Beta-adrenergic_receptor_kinase_2     yes yes 
GAGGYTQSPGG RPA2 DNA-dependent_protein_kinase_catalytic_subunit     yes   
GPHRSTPESRA Presenilin 1 CDK5     yes yes 
ETPAISPSKRA dUTP pyrophosphatase CDC2     yes yes 
NLLPMSPEEFD STAT1 MAPkinase;KIT     yes   
SERRGSHPYID Phosphodiesterase 7A  cAMP-specific  high-affinity Protein_kinase     yes   
RSTPESRAAVQ Presenilin 1 GSK3beta     yes   
LNEEWYVSYIT SLP 76 Lck     yes   
NELKKKASLF Dematin ? / PKA     yes   
YTRVQSMALPP Forkhead box protein L2 PAK1     yes   
NKPTVYGVSPN ABL c-Src / nd     yes   
SAWPGTLRSGM HSP22 ERK1     yes   
QQREKTRWLNS Adducin 1 Rho-kinase     yes   
PGRPLSSYGMD MEK1 PAK1     yes   
IIGEKSFRRSV Protein kinase C, mu PKCmu     yes   
KMAEAYSEIGM T-cell antigen receptor, zeta lck / nd     yes   
HAQDTYLVLDK Erythropoietin receptor JAK2     yes yes 
RTAPYTPNLPH SMAD4 ERK2     yes   
SPYSLSPVSNK HCDH1 CDK2     yes   
RPRSATWPLPR FKHR AKT1     yes   
FSEITSPSKRS ORC1 CDK2     yes   
SLESLYSAASM Grb10 Fyn     yes   
HFPQFSYSASS AKT1 AKT     yes   
FFPFHSPSRLF Crystallin, alpha B nd     yes   
PGTRLSLARMP Glial fibrillary acidic protein CaMKII;PKC;Rho_kinase     yes   
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MRRQRSAPDLK Kinesin family member 1C CK2     yes   
IYSGDYYRQGR c-Mer c-Mer     yes   
SKRRNSEFEIF Tryptophan hydroxylase PRKA1     yes   
RKRRPTSGLHP BRCA1 AKT1     yes   
QFITNSEEVRL MAD2 mitotic arrest deficient-like 1 nd     yes   
VKRRPSPYEME T cell acute lymphocytic leukemia 1 erk1 / T_cell_acute_lymphocytic_leukemia_1       yes 
KFRTPSFLKKN Adducin 3 PKCalpha       yes 
STPAPSRTASF ATP citrate lyase GSK3       yes 
RSRRLTFRKNI Endothelial differentiation gene 1 AKT       yes 
GPRRRSRKPEA Centromeric protein a Aurora_kinase_B       yes 
NGRPDYIIVTQ Aryl hydrocarbon receptor Src /auto       yes 
SHLRNSPEDKR Eukaryotic translation initiation factor 4E bp1 Dual-specificity_tyrosine_phosphorylation-regulated_kinase_2       yes 
KVEPASPPYYS Peroxisome proliferator activated receptor, gamma ERK2_JNK1       yes 
KTNLSYYEYDK Bone marrow kinase BMX FAK       yes 
DHIEVSDDEDE Hsp90 co-chaperone Cdc37 CK2       yes 
EAKRSSADKGV Brain sodium channel 2 PKA       yes 
KEVKRYQATFE Metal regulatory transcription factor 1 Tyrosine_kinase       yes 
EDLSAYASISF IRS 1 PI3K p110a       yes 





Materials and Methods 
 
Antibodies and reagents 
Antibodies for immunoblotting were from Cell Signalling and were used in accordance 
with the supplier's protocol. LPS, Escherichia coli, serotype 0111:B4 was from Sigma. 
 
Bone marrow derived macrophages culture and stimulation 
Bone marrow-derived macrophages (BMDM) were derived from at least three 6- to 8-
week-old mice per experiment and pooled. Cells were seeded on bacteriological plastic 
plates at 106 cells/ml in macrophage growth medium consisting of RPMI 1640 (Gibco-
Invitrogen Ltd, Paisley, UK), 1 mM sodium pyruvate (Gibco), 1 × non-essential amino 
acids (Gibco), 0.029 mM 2-mercaptoethanol (Sigma), 10% heat-inactivated bovine 
Ultra low IgG FCS (Gibco) supplemented with 10% L-cell-conditioned medium as a 
source of CSF-1. After 3 days, non-adherent cells were collected and either 
cryogenically stored in FCS containing 10% DMSO or seeded at 6–8 × 105 cells/ml on 
bacteriological plates and cultured for 4 days before use. Cells were detached using 
EDTA, centrifuged at 1000 g, resuspended in macrophage growth medium and seeded 
for the experiments. All results were obtained from cells that had been cultured for no 
longer than 10 days after dissection. In all experiments described below (unless 
otherwise specified), the medium was changed to macrophage starvation medium 
(=macrophage growth medium without L-cell-conditioned medium) 16–20 h prior to 
the actual experiments. BMDM stimulations were with a vehicle control or 100 ng/ml 
LPS for 10 min at 37 oC before cell lysis.  
 
Preparation of L929-conditioned medium 
Confluent plates of L929 cells (ATCC, American Tissue Culture Collection) were split 
1–10 and cultured with MEM (with Earle salts and l-glutamine) supplemented with 
10% calf serum, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 100 U/ml 
penicillin and 100 μg/ml streptomycin for 7–8 days. The medium was removed, filtered 
through a 0.2-μm membrane and used or stored at − 20 °C. The confluent monolayers 
were cultured with fresh medium for 7 more days to generate a second batch of 
conditioned medium or passaged 1–10. 
 
Peptide arraying 
The production of the array and the protocol of the kinome array have been described in 
detail earlier [24]. In short, cells were washed in PBS and lysed in a non-denaturing 
complete lysis buffer. The peptide arrays (Pepscan, Lelystad, the Netherlands), 
containing up to 1024 different kinase substrates in triplo, were incubated with cell 
lysates for 2 hours in a humidified stove at 37C° together with 33P-γ-ATP or 33P-α-ATP 
(control for non-covalent aspecific binding) as described earlier [22]. Subsequently, the 
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arrays were washed in 2M NaCl, 1% triton-x-100, PBS, 0.1% tween and H2O, where 
after slides were exposed to a phospho-imaging screen for 72 hours and scanned on a 
phospho-imager (Fuji Storm 860, Stanford, GE, USA).  The density of the spots was 
measured and analysed with array software. 
 
Data Analysis of Peptide Array 
For the analysis clustering using the spearman correlation coefficient was calculated for 
each combination of sets and clustering was performed using Johnston hierarchical 
clustering schemes. For each peptide the average and standard deviation of 
phosphorylation was determined and plotted in an amplitude-based hierarchical fashion. 
If only background phosphorylation was present, this amplitude-based distribution can 
be described by a single exponent. Thus determining the exponent describing amplitude 
behaviour of the 250 least phosphorylated peptides should give an adequate description 
of array background phosphorylation and did so in practice. Peptides of which the 
average phosphorylation minus 1.96 times the standard deviation was higher as the 
value expected from describing the background distribution were considered to 
represent true phosphorylation events. Two-sided heteroscedastic T-tests were also 
performed on each set of values to determine significance (p<0.05).  
 
Western blot 
Cells were lysed and immunoblotted for PI3K expression as described before [31]. 
Primary antibodies were detected using fluorescently-labelled species-specific 
secondary antibodies (anti-mouse IRDye 800-conjugated (Rockland) and anti-rabbit 
Alexa-Fluor 680-conjugated (Molecular Probes). Quantification was done using an 
Odyssey infrared scanner (LICOR) using the manufacturer’s software. Signal intensities 
were normalized for an internal loading control such as β-actin or GAPDH. 
 
RNA extraction and real time RT-PCR 
Total RNA was extracted from cells using the RNeasy mini kit (Qiagen, 74104). mRNA 
was subsequently reverse transcribed using SuperScript II Reverse Transcriptase 
(Invitrogen, 18064) and oligo d(T) primers, and subsequently used in  real time RT-
PCR using the QuantiTect SYBR Green PCR Kit (Qiagen 204143). For real time PCR 
amplification TaqMan Universal PCR Mastermix (4304437) and primer mixes 
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